title: Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
authors.affiliation: Department of Medicine, Division of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, USA.
authors.forename: A C
authors.initials: AC
authors.lastname: Spyropoulos
authors.forename: J D
authors.initials: JD
authors.lastname: Douketis
authors.forename: G
authors.initials: G
authors.lastname: Gerotziafas
authors.forename: S
authors.initials: S
authors.lastname: Kaatz
authors.forename: T L
authors.initials: TL
authors.lastname: Ortel
authors.forename: S
authors.initials: S
authors.lastname: Schulman
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000008:administration & dosage / Q000009:adverse effects; D000069604:Dabigatran; D017558:Elective Surgical Procedures; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D006470:Hemorrhage / Q000139:chemically induced / Q000209:etiology*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D002546:Ischemic Attack, Transient / Q000517:prevention & control; D008499:Medical Records / Q000592:standards*; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects; D059035:Perioperative Period; D011720:Pyrazoles / Q000008:administration & dosage / Q000009:adverse effects; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects; D011728:Pyridones / Q000008:administration & dosage / Q000009:adverse effects; D018570:Risk Assessment; D000069552:Rivaroxaban; D020521:Stroke / Q000517:prevention & control; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control*; D015091:beta-Alanine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D009025:Morpholines; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013844:Thiazoles; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran; C552171:edoxaban